Solazyme (SZYM) Misses Q2 EPS by 4c

Solazyme (NASDAQ: SZYM) reported Q2 EPS of ($0.40), $0.04 worse than the analyst estimate of ($0.36). Revenue for the quarter came in at $11.7 million versus the consensus estimate of $14.34 million.

“We are making good progress against our core deliverables, the commercialization of high value products across food, personal care and industrial markets, and the delivery of key milestones at the Moema JV production facility in Brazil,” said Jonathan Wolfson, CEO of Solazyme. “While there is a lot of work ahead, I am proud of the Solazyme team, and what they have accomplished so far this year. I am excited about what is to come.”

“We are maintaining financial discipline in our operations and focusing our sales efforts on strategic revenue streams,” said Tyler Painter, COO and CFO of Solazyme. “On the commercial side, our product portfolio is well aligned with trends across our targeted end markets, and we are seeing a growing number of projects and customers today.”

For earnings history and earnings-related data on Solazyme (SZYM) click here.

You May Also Be Interested In

• ​Trump said he was unaware of his earnings from crypto
• Waste stocks ride AI and healthcare boom as CLH surges 27%
• Lindsay (LNN) Tops Q3 EPS by 18c, Misses on Revenue